The Schall Law Firm Invites Shareholders With Losses In Avid Bioservices, Inc. To Join A Securities Fraud Investigation

LOS ANGELES, CA / ACCESS Newswire / February 26, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.

Accesswire • Feb 26, 2025

An Investigation Has Been Launched Into Avid Bioservices, Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm

LOS ANGELES, CA / ACCESS Newswire / February 25, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.

Accesswire • Feb 25, 2025

Avid Bioservices, Inc. Is Being Investigated For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm

LOS ANGELES, CA / ACCESS Newswire / February 19, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.

Accesswire • Feb 19, 2025

Avid Bioservices Launches New Company Website Designed to Boost Company Brand Awareness and Enhance the Visitor Experience

TUSTIN, Calif., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced the launch of its new corporate website. The new site, which can be visited at www.avidbio.com, combines Avid's elevated brand story and visual identity with improved functionality and navigation, all aimed at enhancing the visitor experience, particularly for current and prospective customers.

GlobeNewsWire • Feb 10, 2025

Avid Bioservices poised for significant growth with new partners GHO Capital and Ampersand Capital Partners

Avid Bioservices poised for significant growth with new partners GHO Capital and Ampersand Capital Partners

GlobeNewsWire • Feb 5, 2025

Avid Bioservices poised for significant growth with new partners GHO Capital and Ampersand Capital Partners

LONDON and BOSTON and TUSTIN, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) -- GHO Capital Partners LLP ("GHO"), the European specialist investor in global healthcare, and Ampersand Capital Partners (“Ampersand”), a private equity firm specialising in growth equity investments in the life sciences and healthcare sectors, today announced the successful closing of the previously announced acquisition of Avid Bioservices (“Avid” of the “Company”), a dedicated biologics Contract Development and Manufacturing Organisation (“CDMO”) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies.

GlobeNewsWire • Feb 5, 2025

Avid Bioservices, Inc. Provides Notice of Fundamental Change and Make-Whole Fundamental Change to Holders of its Convertible Notes in Connection with Completed Merger

TUSTIN, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (“Avid” or the “Company”), a dedicated biologics contract development and manufacturing organization (“CDMO”) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today provided notice (the “Notice”) to holders of its 7.00% Convertible Senior Notes due 2029 (the “Notes”), pursuant to the terms of the Indenture, dated as of March 12, 2024 (the “Indenture”), by and between the Company and U.S. Bank Trust Company, National Association (“U.S. Bank”), as trustee, governing the Notes that, in connection with the closing of the transaction contemplated by the Agreement and Plan of Merger, dated as of November 6, 2024 (the “Merger Agreement” and such transaction, the “Merger”), by and among Avid, Space Finco, Inc. and Space Mergerco, Inc., a Fundamental Change and a Make-Whole Fundamental Change (each as defined in the Indenture) occurred under the Indenture on February 5, 2025.

GlobeNewsWire • Feb 5, 2025

Avid Bioservices, Inc. Is Being Investigated For Securities Law Violations And Affected Investors Are Urged To Contact The Schall Law Firm

LOS ANGELES, CA / ACCESS Newswire / February 2, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.

Accesswire • Feb 2, 2025

The Schall Law Firm Invites Shareholders With Losses To Join An Investigation Into Avid Bioservices, Inc. For Securities Fraud

LOS ANGELES, CA / ACCESS Newswire / February 1, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.

Accesswire • Feb 1, 2025

Avid Bioservices, Inc. Is Being Investigated For Securities Law Violations And Impacted Investors Are Urged To Contact The Schall Law Firm

LOS ANGELES, CA / ACCESS Newswire / January 31, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.

Accesswire • Jan 31, 2025